$SOTK

Sono-Tek (SOTK) director adds 5,396 long-dated options

Sono-Tek (SOTK) director Carol A. O'Donnell received 5,396 long-dated options with a $5.35 exercise price, exercisable from 2027-08-20 and expiring 2036-08-20, increasing her total options to 30,773. The options are tied to Sono-Tek common stock.

Original reporting
Published Aug 24, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SOTK
Neutral
high confidence
Mentioned
$SOTK
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$SOTKNeutralLow
01

Why it matters

The grant adds to the director's equity exposure but does not provide new strategic information about the company.

02

Market read

Routine insider compensation filing with limited market impact.

03

What to watch

Potential future dilution if many similar grants are issued to other insiders.

Relevance 4/10Novelty 4/10Timing: reported 2026-08-20

Background

Form 4 filing discloses a director's option award; typical corporate governance disclosure.

Company-level read

Ticker impact

$SOTKNeutralHigh confidence
Context

Director Carol A. O'Donnell was granted 5,396 options at $5.35 exercise price, increasing her holdings to 30,773 options.

Expected impact

No significant price impact expected.

Evidence & confidence

The grant is a routine compensation event for a director, valued at about $29K, which is material only for the insider, not the market.

Market effects

None

None

None

Counterpoint

Even small insider grants can signal confidence, but the size here is too trivial to affect sentiment.

Key entities

  • Carol A. O'Donnell

    Recipient of the option grant.

  • Sono-Tek Corp

    Issuer of the options.

Related articles

$SOTKMed

Sono-Tek Reports Fiscal Second Quarter and First Half 2027 Results Driven by Strong Medical Sector and Higher Value Production Systems

SONO TEK CORP (SOTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sono-Tek Reports Fiscal Second Quarter and First Half 2027 Results Driven by Strong Medical Sector and Higher Value Production Systems First Half Revenue Increased 6% to $10.9 Million; Gross Margin Expanded to 55%; Operating Income Increased 41%; Medical Market Sales

$SOTKMed

Sono-Tek stock rises on record $3.6M production line order

Sono-Tek Corp (NASDAQ:SOTK) shares rose 3.9% premarket after the company said it received a $3.6 million order for an integrated advanced manufacturing production line for medical diagnostic device coating. Sono-Tek said it is its largest single-line order, placed by an existing customer moving to high-volume manufacturing, with shipment expected in fiscal 2028.

$SOTKMedAI 8/10

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

Sono-Tek (Nasdaq: SOTK) reported first-quarter fiscal 2027 results for the quarter ended May 31, 2026. Net sales rose 10% to $5.66 million, gross margin expanded to 57% from 52%, operating income increased 86% to $897,000, and net income rose to $741,000 ($0.05 diluted). Cash was $16.65 million with no debt, and backlog was $7.73 million. The company expects continued 1H growth driven by medical demand and higher-value production systems.

$SOTKMed

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

SONO TEK CORP (SOTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm SONO-TEK CORPORATION REPORTS FIRST QUARTER FISCAL 2027 RESULTS Exhibit 99.1 Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results Revenue Increased 10%; Gross Margin Expanded to 57%; Operating Income Increased 86%; Net Income Increased 67% Anticipati

$SOTKMedAI 9/10

Sono-Tek Corporation Q4 2026 Earnings Call Summary

Sono-Tek Corporation reported Q4 2026 results driven by a shift to higher-ASP, turnkey production systems. The company said medical demand rose 54% year over year, while clean energy orders fell 19% amid government policy changes. Gross margin increased to 51% and operating income rose 81%. Management projected growth and profitability in fiscal 2027 H1, with flat-to-modestly higher full-year revenue amid clean-energy uncertainty. Cash was $14.8 million with no debt.